methocarbamol Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1747 | 532-03-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A centrally acting muscle relaxant whose mode of action has not been established. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1206)
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 3 | g | O |
| 3 | g | P |
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 16, 1957 | FDA | AUXILIUM PHARMS LLC |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Necrosis ischaemic | 63.58 | 12.19 | 20 | 17176 | 825 | 46668041 |
| Pneumonia streptococcal | 53.46 | 12.19 | 21 | 17175 | 1674 | 46667192 |
| Muscle spasms | 50.37 | 12.19 | 128 | 17068 | 122985 | 46545881 |
| Beta haemolytic streptococcal infection | 47.88 | 12.19 | 20 | 17176 | 1869 | 46666997 |
| Acquired haemophilia | 45.84 | 12.19 | 16 | 17180 | 915 | 46667951 |
| Completed suicide | 44.20 | 12.19 | 136 | 17060 | 145784 | 46523082 |
| Gallbladder polyp | 40.90 | 12.19 | 14 | 17182 | 755 | 46668111 |
| Multiple drug therapy | 38.58 | 12.19 | 14 | 17182 | 897 | 46667969 |
| Diabetes mellitus inadequate control | 31.28 | 12.19 | 31 | 17165 | 13183 | 46655683 |
| Migraine | 25.74 | 12.19 | 70 | 17126 | 69956 | 46598910 |
| Drug hypersensitivity | 24.73 | 12.19 | 164 | 17032 | 243661 | 46425205 |
| Spinal operation | 23.24 | 12.19 | 18 | 17178 | 5522 | 46663344 |
| Fibromyalgia | 22.87 | 12.19 | 45 | 17151 | 36418 | 46632448 |
| Analgesic drug level increased | 22.50 | 12.19 | 11 | 17185 | 1483 | 46667383 |
| Rheumatoid arthritis | 22.05 | 12.19 | 34 | 17162 | 240181 | 46428685 |
| Treatment failure | 21.72 | 12.19 | 4 | 17192 | 93083 | 46575783 |
| Anxiety | 21.30 | 12.19 | 127 | 17069 | 181830 | 46487036 |
| Pain | 20.69 | 12.19 | 267 | 16929 | 476681 | 46192185 |
| Neutropenia | 20.22 | 12.19 | 14 | 17182 | 143190 | 46525676 |
| Withdrawal syndrome | 18.82 | 12.19 | 28 | 17168 | 18106 | 46650760 |
| Amnesia | 18.81 | 12.19 | 45 | 17151 | 41586 | 46627280 |
| Back pain | 18.76 | 12.19 | 137 | 17059 | 209902 | 46458964 |
| Road traffic accident | 18.32 | 12.19 | 32 | 17164 | 23659 | 46645207 |
| Hypertension | 18.06 | 12.19 | 129 | 17067 | 196227 | 46472639 |
| Cardiac failure | 17.48 | 12.19 | 4 | 17192 | 79944 | 46588922 |
| Maternal exposure during pregnancy | 17.38 | 12.19 | 8 | 17188 | 102541 | 46566325 |
| Infusion related reaction | 16.99 | 12.19 | 8 | 17188 | 101200 | 46567666 |
| Febrile neutropenia | 16.64 | 12.19 | 7 | 17189 | 94620 | 46574246 |
| Contusion | 16.57 | 12.19 | 70 | 17126 | 87417 | 46581449 |
| Intervertebral disc protrusion | 16.35 | 12.19 | 28 | 17168 | 20377 | 46648489 |
| Thyroiditis chronic | 15.90 | 12.19 | 3 | 17193 | 12 | 46668854 |
| Illness | 15.85 | 12.19 | 21 | 17175 | 12203 | 46656663 |
| Livedo reticularis | 15.76 | 12.19 | 10 | 17186 | 2234 | 46666632 |
| Blood pressure inadequately controlled | 15.68 | 12.19 | 13 | 17183 | 4393 | 46664473 |
| Somnolence | 15.67 | 12.19 | 105 | 17091 | 156416 | 46512450 |
| Back disorder | 15.55 | 12.19 | 18 | 17178 | 9123 | 46659743 |
| Exercise tolerance decreased | 15.24 | 12.19 | 13 | 17183 | 4564 | 46664302 |
| Respiratory arrest | 14.68 | 12.19 | 36 | 17160 | 33780 | 46635086 |
| Depression | 14.63 | 12.19 | 110 | 17086 | 169994 | 46498872 |
| Fall | 14.55 | 12.19 | 185 | 17011 | 328912 | 46339954 |
| Drug intolerance | 14.27 | 12.19 | 20 | 17176 | 147029 | 46521837 |
| Oesophagitis | 14.06 | 12.19 | 21 | 17175 | 13630 | 46655236 |
| Surgery | 13.97 | 12.19 | 32 | 17164 | 28753 | 46640113 |
| Loss of consciousness | 13.59 | 12.19 | 77 | 17119 | 108161 | 46560705 |
| Therapeutic reaction time decreased | 13.55 | 12.19 | 7 | 17189 | 1061 | 46667805 |
| Exposure during pregnancy | 13.48 | 12.19 | 12 | 17184 | 108200 | 46560666 |
| Therapy cessation | 13.36 | 12.19 | 30 | 17166 | 26599 | 46642267 |
| Gastrointestinal haemorrhage | 13.17 | 12.19 | 6 | 17190 | 77367 | 46591499 |
| Pre-existing condition improved | 12.92 | 12.19 | 14 | 17182 | 6598 | 46662268 |
| Off label use | 12.64 | 12.19 | 85 | 17111 | 379756 | 46289110 |
| Pancytopenia | 12.43 | 12.19 | 8 | 17188 | 85050 | 46583816 |
| Intervertebral disc disorder | 12.30 | 12.19 | 11 | 17185 | 4111 | 46664755 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug dependence | 53.95 | 14.73 | 44 | 7522 | 21251 | 29923661 |
| Victim of child abuse | 39.24 | 14.73 | 10 | 7556 | 280 | 29944632 |
| Phonophobia | 37.26 | 14.73 | 8 | 7558 | 103 | 29944809 |
| Depression | 30.26 | 14.73 | 69 | 7497 | 90368 | 29854544 |
| Respiratory depression | 23.46 | 14.73 | 21 | 7545 | 11482 | 29933430 |
| Back pain | 22.67 | 14.73 | 67 | 7499 | 102529 | 29842383 |
| Child abuse | 22.12 | 14.73 | 6 | 7560 | 215 | 29944697 |
| Poisoning deliberate | 21.13 | 14.73 | 15 | 7551 | 5889 | 29939023 |
| Suicide attempt | 20.82 | 14.73 | 35 | 7531 | 36662 | 29908250 |
| Memory impairment | 20.48 | 14.73 | 35 | 7531 | 37139 | 29907773 |
| Back injury | 20.05 | 14.73 | 12 | 7554 | 3533 | 29941379 |
| Spinal operation | 19.06 | 14.73 | 10 | 7556 | 2286 | 29942626 |
| Back disorder | 18.66 | 14.73 | 14 | 7552 | 5980 | 29938932 |
| Product prescribing error | 18.54 | 14.73 | 22 | 7544 | 16711 | 29928201 |
| Serum procollagen type III N-terminal propeptide increased | 17.27 | 14.73 | 4 | 7562 | 74 | 29944838 |
| Post-traumatic neck syndrome | 15.60 | 14.73 | 4 | 7562 | 115 | 29944797 |
| Anxiety | 15.56 | 14.73 | 54 | 7512 | 89817 | 29855095 |
| Insomnia | 15.23 | 14.73 | 55 | 7511 | 93281 | 29851631 |
| Suicidal ideation | 14.87 | 14.73 | 30 | 7536 | 36084 | 29908828 |
| Pain | 14.78 | 14.73 | 84 | 7482 | 172557 | 29772355 |
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | M03BA03 | MUSCULO-SKELETAL SYSTEM MUSCLE RELAXANTS MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS Carbamic acid esters |
| ATC | M03BA53 | MUSCULO-SKELETAL SYSTEM MUSCLE RELAXANTS MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS Carbamic acid esters |
| ATC | M03BA73 | MUSCULO-SKELETAL SYSTEM MUSCLE RELAXANTS MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS Carbamic acid esters |
| FDA PE | N0000175730 | Centrally-mediated Muscle Relaxation |
| FDA EPC | N0000175737 | Muscle Relaxant |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D009125 | Muscle Relaxants, Central |
| MeSH PA | D009465 | Neuromuscular Agents |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| CHEBI has role | CHEBI:51371 | muscle relaxants |
Drug Use (View source of the data)
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Spasticity | indication | 221360009 | |
| Muscle Spasm with Pain | indication | ||
| Tetanus Adjunct Treatment | indication | ||
| Alcoholism | contraindication | 7200002 | |
| Peptic ulcer | contraindication | 13200003 | DOID:750 |
| Gastrointestinal ulcer | contraindication | 40845000 | |
| Vitamin K deficiency | contraindication | 52675005 | DOID:11249 |
| Nasal polyp | contraindication | 52756005 | |
| Acute nephropathy | contraindication | 58574008 | |
| Factor II deficiency | contraindication | 73975000 | |
| Reye's syndrome | contraindication | 74351001 | DOID:14525 |
| Gastrointestinal hemorrhage | contraindication | 74474003 | |
| Thrombotic thrombocytopenic purpura | contraindication | 78129009 | DOID:10772 |
| Gout | contraindication | 90560007 | DOID:13189 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Hemophilia | contraindication | 90935002 | |
| Anemia due to enzyme deficiency | contraindication | 111577008 | |
| von Willebrand disorder | contraindication | 128105004 | DOID:12531 |
| Seizure disorder | contraindication | 128613002 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Anemia | contraindication | 271737000 | DOID:2355 |
| Pregnancy, function | contraindication | 289908002 | |
| Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Acute erosive gastritis | contraindication | 444926003 |
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Carbonic anhydrase 1 | Enzyme | INHIBITOR | Ki | 7.60 | IUPHAR | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4017879 | VUID |
| N0000146232 | NUI |
| D00402 | KEGG_DRUG |
| 4017879 | VANDF |
| C0025659 | UMLSCUI |
| CHEBI:6832 | CHEBI |
| CHEMBL1201117 | ChEMBL_ID |
| D008721 | MESH_DESCRIPTOR_UI |
| DB00423 | DRUGBANK_ID |
| 6829 | IUPHAR_LIGAND_ID |
| 776 | INN_ID |
| 125OD7737X | UNII |
| 4107 | PUBCHEM_CID |
| 6845 | RXNORM |
| 5075 | MMSL |
| 988 | MMSL |
| d00965 | MMSL |
| 001669 | NDDF |
| 387486000 | SNOMEDCT_US |
| 83973001 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-1290 | TABLET | 500 mg | ORAL | ANDA | 21 sections |
| Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-1292 | TABLET | 750 mg | ORAL | ANDA | 21 sections |
| Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0440-1740 | TABLET | 500 mg | ORAL | ANDA | 23 sections |
| Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0517-1825 | INJECTION | 100 mg | INTRAMUSCULAR | ANDA | 20 sections |
| ROBAXIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6103 | INJECTION | 100 mg | INTRAMUSCULAR | NDA | 22 sections |
| ROBAXIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6217 | INJECTION | 100 mg | INTRAMUSCULAR | NDA | 22 sections |
| Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7057 | TABLET | 500 mg | ORAL | ANDA | 22 sections |
| Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7058 | TABLET | 750 mg | ORAL | ANDA | 22 sections |
| Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-664 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 19 sections |
| Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-665 | TABLET, FILM COATED | 750 mg | ORAL | ANDA | 19 sections |
| Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-259 | TABLET | 750 mg | ORAL | ANDA | 21 sections |
| Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-464 | TABLET | 750 mg | ORAL | ANDA | 22 sections |
| Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-622 | TABLET | 750 mg | ORAL | ANDA | 19 sections |
| Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-773 | TABLET | 500 mg | ORAL | ANDA | 22 sections |
| Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-956 | TABLET | 750 mg | ORAL | ANDA | 23 sections |
| METHOCARBAMOL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-147 | TABLET | 500 mg | ORAL | ANDA | 21 sections |
| METHOCARBAMOL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-148 | TABLET | 750 mg | ORAL | ANDA | 21 sections |
| ROBAXIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-981 | TABLET, FILM COATED | 750 mg | ORAL | NDA | 11 sections |
| METHOCARBAMOL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17511-505 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 20 sections |
| METHOCARBAMOL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17511-506 | TABLET, FILM COATED | 750 mg | ORAL | ANDA | 20 sections |
| Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-078 | TABLET | 500 mg | ORAL | ANDA | 21 sections |
| Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-079 | TABLET | 750 mg | ORAL | ANDA | 21 sections |
| Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-675 | INJECTION, SOLUTION | 100 mg | INTRAVENOUS | ANDA | 23 sections |
| Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 31722-533 | TABLET | 500 mg | ORAL | ANDA | 19 sections |
| Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 31722-534 | TABLET | 750 mg | ORAL | ANDA | 19 sections |
| Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-072 | TABLET | 750 mg | ORAL | ANDA | 21 sections |
| Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-130 | TABLET | 500 mg | ORAL | ANDA | 21 sections |
| Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 35561-211 | TABLET, COATED | 750 mg | ORAL | ANDA | 19 sections |
| Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 35561-212 | TABLET, COATED | 500 mg | ORAL | ANDA | 19 sections |
| Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 35573-413 | TABLET, COATED | 500 mg | ORAL | ANDA | 19 sections |